OmniAb, Inc. (OABI) Earnings Call Transcript & Summary

March 20, 2024

NASDAQ US Health Care Life Sciences Tools and Services earnings 53 min

Earnings Call Speaker Segments

Kurt Gustafson

executive
#1

Thanks, Operator, and good afternoon to all of you. Kurt Gustafson here, as you mentioned, and I appreciate everyone taking the time to participate in the conference call covering our 2023 fourth quarter and full year financial results. Slides have been prepared to go along with today's prepared remarks, and you can find them in the investors section of our website, omniab.com. Before we get started, I want to remind those listening that during this call, comments will include forward-looking statements as defined under the federal securities laws. Risks and uncertainties are associated with these forward-looking statements, and they could cause actual results to differ materially from any anticipated results. The cautionary statements in today's press release and our SEC filings qualify these forward-looking statements. Before we begin, I want to flag that what you're hearing on this conference call is time-sensitive, and it's only accurate as of today's live broadcast — March 20th, 2024. Unless the law demands otherwise, OmniAb has no obligation to go back and revise or update any forward-looking statements because of events or circumstances that arise after this call. On the line with me today is OmniAb's President and CEO, Matt Foehr. Matt and I will walk you through highlights of the company's operations, updates on our partners and technology, and our recent financial results. Once we finish our prepared remarks, we'll take your questions. So with that, I'll hand things over to Matt.

Matt Foehr

executive
#2

Thank you, Kurt, and good afternoon to all of you, and I appreciate you being here for the call covering both our fourth quarter and full year 2023 results. To begin today, I want to note that OmniAb's clear purpose is to speed up the creation of breakthrough therapies by advancing the boundaries of drug discovery technology. This happens inside a pure-play licensing operation that centers on partnerships, one built for efficiency, scalability, and strong leverage, and which we feel is now ready to expand in response to what we view as a lasting, worldwide requirement within pharma. The most pressing difficulties in antibody-focused drug discovery are what our technology portfolio targets. Ours is a deeply differentiated collection of technologies that have been validated and can be leveraged more and more. Rising industry success rates, along with other drivers, are fueling faster investment in antibody work across pharma, and we believe our position is strong when it comes to satisfying greater appetite for advanced, antibody-centered discovery platforms. OmniAb achieved meaningful growth during 2023, advancing considerably on several essential fronts of our operations. Among these were broadening our roster of partners and our pipeline of partnered programs, progress on significant late-stage programs by certain partners, and worldwide enlargement of our business development team. Today we have BDT personnel across the U.S. as well as in Asia, operating from Singapore, and in Europe. Our commitment is to ongoing innovation, and we carried that out exceptionally well during 2023 by launching 2 new technologies successfully, among them OmniDeep, our collection of in silico, AI, and machine learning technologies and capabilities integrated across our technology stack and pairing exceptionally well with the biological intelligence found in our transgenic animals. During November, we introduced OmnidAb, the newest illustration of an innovative transgenic animal, and I'll cover that in more detail soon; our first complete year as an independent public company brought an impressive set of accomplishments, yet we stay focused on expanding technological limits so we can keep serving our partners' needs both currently and down the road. An internal technology innovation engine that grows more efficient by the day helps shape how we expect to generate long-term value for every one of our stakeholders. With this momentum from 2023 as our foundation, we anticipate further growth in the coming year. Now, on slide number five, a number of our business metrics are displayed, and these graphs largely require no explanation and in my view plainly demonstrate that 2023 brought yet another period of considerable growth and advancement for our business. Even with sector-related and macro headwinds during the past year, our key performance indicators kept delivering outstanding results. Our active partners climbed to 77, up from 69 a year earlier, which equals a 12% rise. Active partner programs likewise rose 12%, going up to 325 from 291. Finally, active clinical and approved programs went up 23%, since we finished 2023 with 32 versus 26 at the close of 2022. I'd like to emphasize that every figure I'm citing is calculated after subtracting attrition, and it's worth noting that attrition is a normal occurrence that should be anticipated in the discovery and development of pharmaceuticals. Now let me go into a bit more depth regarding our partnership base, which is shown on slide 6. We had a very productive 2023 when it came to adding new partners, since our count of active partners kept increasing on a net-of-attrition basis; several elements fueled that growth, among them the visibility of our platform, clinical and commercial proof of our technologies, and a broader business development and marketing footprint supported by our leading-edge science and the launches of our new technologies. Because we remain focused on licensing as a way to align our interests with those of our partners, we are drawing in and onboarding a varied group of partners to power the next wave of discovery and preclinical candidates moving toward the clinic. Now turning to slide number 7, where we give a more detailed look at the new platform licensing deals we struck last year. During 2023 we signed 10 new licenses, and today we are revealing new platform deals with Enable Life Sciences and also with a startup company, both of which were signed during the fourth quarter, together with a big pharma partnership previously disclosed that was likewise executed in Q4. As I mentioned, across the entire year of 2023 we signed 10 new deals. As the chart here shows, 2 involved well-established global big pharma players, plus deals with new biotech partners and academic partners. We brought in 4 additional deals with startup partners, and I want to point out that 40% of our deals were struck with startup companies even though funding for smaller or new biotech companies fell significantly in 2023. In our view, this variety of new partners represents a strength for our business. Keeping up our business record of execution, we have also observed solid growth and advancement of active programs, and I'm now on slide number 8. As I noted, we entered 2023 with 291 active programs and expanded to 325 active programs net of attrition. That growth is visible on the left-hand side in the bar chart. The pie chart on the right provides a breakdown of our 325 active programs according to stage of development. By the close of 2023, our expanding discovery phase was made up of 278 programs along with 15 programs in the preclinical stage. It's important to note that we classify preclinical stage programs as those confirmed to be in pre-IND or IND-enabling studies. Over the course of 2023, 6 programs advanced from preclinical into phase 1 clinical trials. At year's end, we had 25 programs in phase 1 trials, and I should also mention that one program progressed from phase 3 to its first international registration filing. Given these strong leading metrics, it's also encouraging to see that we have preserved and are continuing to build momentum for growth in active clinical programs, which appear here on slide number 9. At the beginning of 2023, we said we anticipated our partners would kick off three to five fresh clinical programs, and by the time the year wrapped up, six new clinical starts had occurred. Just to give a quick sample, Seagen revealed it had launched a first-in-human phase 1 trial for SGN-BB228, a bispecific aimed at CD228 and 4 to 1BB for advanced melanoma along with other solid tumors. Following the completion of Pfizer's purchase of Seagen, that program now sits within Pfizer's pipeline, and moving forward it will be identified by its Pfizer project number. Immunovant kicked off a Phase 1 trial for IMVT-1402, its next generation anti-FcRn, in autoimmune diseases, while Cessation launched a phase 1 study of CSX-1004, a monoclonal antibody generated from OmniRat and engineered specifically to stop fentanyl overdose. In Q4, BioCity Biopharma reported that the first patient had been dosed with BC3195, its first-in-class CDH3 targeting antibody-drug conjugate, in a Phase 1 trial taking place in China. Several of our other partners also shared updates on additional clinical and commercial stage assets during the fourth quarter, and a few of those were laid out in the press release we put out once the market closed today. From what our partners tell us, we foresee roughly four to six new additions to clinical development for novel OmniAb-derived antibodies during 2024.

Matt Foehr

executive
#3

Like I said, we're dedicated to keeping up the pace of innovation on our platform, and thanks to the way our relationships work, we enjoy an excellent view of both the industry's present state and its future direction. That shapes the technologies we create and bring to market. In the past year, we introduced OmniDeep and OmnidAb, and you can see both of them referenced on slide 10, inside the pair of green boxes positioned at the lower left. I want to draw attention to the OmnidAb technology, which came out in Q4, since it is rapidly turning into one more important differentiator for us here at OmniAb. A cornerstone of our business is our innovative transgenic animals. Our view is that new antibodies produced in vivo outperform those from other sources, since they undergo natural optimization via an iterative process that preferentially chooses antibodies possessing outstanding specificity and developability profiles. The capacity of our engineered transgenic animals' immune systems to generate optimized antibodies for human therapeutics is something we refer to as biological intelligence. We think this method boosts efficiency and the odds of success for our partners and puts our business in an extremely strong position. OmnidAb is our newest illustration of that. As outlined here on slide 11, it is the first and only transgenic chicken to produce single-domain antibodies — a new antibody class discovered naturally in camelids that is being increasingly harnessed across a range of therapeutic uses. OmnidAb is an innovative in vivo platform built on a human VH scaffold that undergoes affinity maturation within a chicken host to deliver a functionally diverse immune repertoire of antibodies that mammalian systems cannot provide. Put simply, single-domain antibodies offer modular building blocks that can be put together in different formats to match the biology of whatever application is desired. On this slide you can also see some of what our partners tell us regarding the technology, since several partners are now employing it in active programs. We anticipate that many additional partners will start programs with OmnidAb during this year and the next one. This stems partly from the distinctive physical characteristics of single-domain antibodies, which are laid out here on slide number 12; it can be expressed on its own as a unit, and its compact format creates new and significant opportunities from a scientific and medical standpoint. Single-domain antibodies can be used for valuable applications. They can unlock alternative administration routes, as we show here on slide 13. They can result in greater penetration and adjustable clearance, and also in fresh opportunities and fresh markets for us in imaging, in diagnostics, in theranostics, and in radiotherapy. They also carry wide therapeutic potential in bi and multispecifics and CAR-T therapy, along with pursuing therapeutics for CNS and neurodegenerative diseases, which clearly are areas of considerable interest to our partners. Now, as we turn to the present year here on slide 14, besides anticipating 4 to 6 new clinical programs, we expect to witness late-stage progress for a number of key programs at Genmab, at Immunovant, and others. Additionally, we anticipate that advancements in certain of our ion channel initiatives carrying greater value, conducted alongside worldwide large pharmaceutical collaborators, will draw increased attention from both the investment community and the broader research sector, and that genuinely excites us. At present, we possess a business development group that is completely staffed, along with an innovation and support engine that operates more efficiently, which we intend to utilize for broadening deals across the globe; our ongoing emphasis will remain on innovation and broadening our technology platform, plus bringing in novel technology, fresh workflows, and improved experiences for partners, all of which we will discuss at scientific and technical gatherings throughout the year. Having said that, I'll hand the call back to Kurt so he can walk us through the financials. Kurt?

Kurt Gustafson

executive
#4

Thank you, Matt. Please stay with me one last time while I cover the historical financials. For periods before November 1st, 2022, the results we're reporting were put together on a carve-out basis, taken from Ligand's historical accounting records as though OmniAb had operated as a standalone company. Because of that, some comparisons become tricky, especially on the operating expense line, since corporate structure and reporting methods differed. Now on slide 16, here's a summary of how we performed financially in Q4 of 2023. Revenue totaled $4.8 million for that quarter, versus $35.3 million during the same quarter a year earlier. That decline mostly reflects the $25 million Tecvayli milestone we recognized in Q4 of 2022. Service revenue came in lower, largely because work wrapped up on several ion channel programs, while royalty revenue was roughly flat year over year. On the operating expense side, R&D for Q4 reached $14.8 million, up from $12.9 million in the comparable quarter last year. That rise was driven mainly by greater personnel costs and money put into our new facilities. G&A came in at $7.9 million, down from $10.2 million in the year-ago quarter. The drop in G&A reflects transaction costs tied to the spinoff that had been recorded in Q4 of 2022. Partly offsetting that was increased headcount-related expense, since we expanded the G&A side of the business throughout 2023. We posted a net loss of $14.1 million, or $0.14 per share, in Q4, compared with net income of $6.8 million, or $0.07 per share, a year earlier. One more item I'd like to flag concerns our tax rate in Q4. During the fourth quarter of 2023, we booked a one-time benefit, mostly stemming from a deduction for transaction-related expenses connected to the spinoff. Setting aside one-time items, we'd generally anticipate a tax rate near 20% moving forward. Now to the full year figures on slide 17: for 2023, revenue came to $34.2 million, against $59.1 million for 2022. License and milestone revenue declined from the previous year. What mainly separates the two years is how the Tecvayli milestones were recognized. Back in 2022, we recorded a $25 million Tecvayli milestone tied to the U.S. commercial launch, whereas in 2023 we recorded a $10 million milestone for the EU launch. Keep in mind, though, that cash for both of those milestones actually came in during 2023. Service revenue fell relative to the prior year, chiefly because work finished on several ion channel programs. Operating expense for 2023 was roughly $103.6 million, versus $85.7 million in 2022. We experienced a rise in R&D expenses tied to greater headcount rather than the money put into our new facilities during 2023; on the G&A side, costs went up because we were constructing our G&A infrastructure, and that covered both personnel and the typical public company expenses that weren't present in the cost structure for the bulk of 2022. Our net loss for 2023 came to $50.6 million, or $0.51 per share, compared with a net loss of $22.3 million, or $0.26 a share, in 2022. During 2023 we set up our operations as a standalone public company and built a foundation for growing the business. If you look at the total operating expense line on slide 18, you can see that operating expense has flattened out at roughly $26 million each quarter. Still, bear in mind that a significant share of our operating expense is non-cash. That said, we now possess the staff and facilities we think will be enough to sustain the operation's growth far into the future. Importantly, we anticipate continuing to add partners and programs, yet because of the leverage embedded in our business, that expansion will call for only minimal extra headcount moving forward. Consequently, we expect operating expense for 2024 to be roughly equal to what it was in 2023; this sets our business apart, since our workstreams draw on the biological intelligence inherent in our transgenic animals to uncover new molecules. Moving to slide 19 and reviewing the balance sheet along with our cash position, we closed the year with $87 million in cash, compared with a starting cash balance of $88.3 million. The sole other significant balance sheet change worth noting was the decrease in accounts receivable, which stemmed from collecting those Tecvayli milestones. To lay out our projected cash position going forward, I believe it's key to grasp what components drove our cash burn in 2023, as shown here on slide 20. Looking at the hashed black bars in the chart on the right, you'll find our actual quarterly cash flows for 2023. They indicate that net cash used across the entire year was $1.3 million. That said, this benefited from receiving a $35 million payment for the Tecvayli milestones, and both of those came in during Q1 of 2023. The blue bars represent cash burn without that payment, revealing that pro forma cash burn averaged roughly $9 million each quarter, amounting to $36.3 million for the year. Looking forward to 2024, we expect our cash use to be fairly comparable to the cash use in 2023 once you set aside the $35 million Tecvayli milestone payment we got in 2023. Yet, in contrast to 2023, the timing of our cash burn will be weighted more toward the front half of 2024. The first quarter tends to be when we burn the most cash, because of items tied to the compensation cycle. For 2024, our projection is that milestone payments will skew toward the back half of the year, which reflects the most recent information from our partners as well as public statements they have made. Turning to the next year, given how we expect our existing partnered pipeline to progress, we anticipate that cash use during 2025 will be significantly less than during 2024; our expectation remains that the cash we currently hold plus cash generated by operations ought to give us enough capital to fund operations into the foreseeable future. This longer-term cash view rests on a model that projects cash inflows from every one of our current partner programs, using standard industry timelines for clinical development and applying standard industry probabilities of success; as an illustration, at the close of 2023 we had 25 programs in phase 1 studies. Applying standard industry probabilities, roughly half of them should reach a Phase 2 study. Drawing on industry averages, we work out how long a program would remain in a Phase 1 study prior to advancing to a Phase 2 study. The contracted Phase 2 milestone payment is then multiplied by that probability to arrive at our projected milestone payment. Of course, in reality we will never receive half of a milestone payment. Still, with the quantity of programs currently under development, we think this methodology offers a reasonable means of forecasting future revenue. Another thing to note is that this cash outlook leaves out any kind of strategic technology acquisition. With that, I'll hand it to Matt for a few closing comments, and then we'll open up the call to Q&A.

Matt Foehr

executive
#5

I appreciate that, Kurt. Let me stress once more that a little more than 12 months after wrapping up our spinoff and starting life as a standalone business, we have achieved significant progress when it comes to executing on our operations. OmniAb stands ready to grow, and thanks to the group we have brought together and the money we had already put into the business, it is now extremely scalable and extremely leverageable. Our organizational focus here rests on our stakeholders, whom we regard as our team, our partners, and the patients whom their programs treat or will treat, the communities in which we operate, and naturally, and crucially, our investors. So with that said, I will hand the call back to the operator at this point so we can begin taking questions. Operator?

Puneet Souda

analyst
#6

Hi, everyone. I appreciate you taking these questions. To start, Matt, could I ask about the broader expectations — you came in above that. Program counts also came in higher. So I'm just trying to break down what portion of this reflects biotech fundraising alone, plus the M&A activity we've witnessed during the opening three months of this year, versus what portion comes from additional business development discussions. Would you be able to separate those for us? Also, perhaps you were already noticing some impact back in 2023, so tell us about what you observed as 2023 wrapped up and what the business development conversation has looked like during this first quarter too.

Matt Foehr

executive
#7

Yes. Yes, Puneet, I appreciate that. Your question carries an assumption, and like you mentioned, we're emerging from 2022 and 2023, a stretch when biotech funding broadly declined considerably, correct? Companies on the smaller side, in particular, struggled to bring in capital. Large pharmaceutical firms, being well-established, were examining their pipelines closely and directing their attention toward specific assets or therapeutic areas; and even so, throughout 2022 and 2023, we experienced genuinely solid expansion, net of attrition, both in active partners and in active programs. Actually, measured by the count of new licenses, 2022 and 2023 ranked among our strongest growth years. In certain respects, separating the different factors behind that expansion can be tricky, correct? Throughout last year we were growing our business development team. We enjoyed decent visibility for the platform, largely thanks to greater investment in innovation and the rollout of new technologies, along with favorable headlines from partners making good clinical progress. So I believe each of those factors contributes to the growth we're experiencing. It's evident that the industry overall seems to have begun this year well, particularly in comparison with 2022 and 2023; and we feel that genuinely places our technology in a strong position, given the validation, visibility, and momentum we're accumulating. So with luck, that provides you with a bit more detail.

Puneet Souda

analyst
#8

Yeah, that helps, Matt. Could you say a bit about single-domain antibodies? You mentioned a couple of places where they might work. Thinking about your earlier product launches, maybe just tell us how you'd rank this one, what kind of interest you're seeing, and what you expect for growth in this technology?

Matt Foehr

executive
#9

Yeah, thanks, Puneet. As far as how much interest OmnidAb has drawn, I honestly can't think of another technology we've brought in or rolled out that generated more attention right out of the gate. Really, the instant we introduced it — once partners knew it was on the way — we were already doing antigen work for a number of programs. Today we have several partners using the technology, and some of them are running multiple programs; I'd say it's a technology launch that landed at just the right moment from several angles. Of course, everything is still at the discovery stage right now, but the conversations we'd been having with partners across the prior couple of years shaped our confidence about the demand for a single-domain technology such as OmnidAb that can harness the chicken host, particularly when combined with our screening and the other technologies threaded through our stack. So yeah, we feel great about the work already underway, the discussions, and the deliverables already going out to partners — the earliest users, who began at the end of last year. And yeah, we're thrilled about what it does for how the business is positioned.

Puneet Souda

analyst
#10

Understood. All right, that's really useful. I'll get back in line.

Joe Pantginis

analyst
#11

Hello, everyone. Good afternoon, and thanks for fielding the question. Before I get to my questions, honestly, I find it quite encouraging right now, having modeled both sides of the business going back to the Ligand days, to actually hear about the efficiencies you currently have in place and that adding employees isn't really necessary to that degree even while your program count expands. So that's really good to hear. So my first question, I suppose, starting at a high level, and not to sound—well, you're already pursuing cutting-edge technologies when it comes to antibody discovery. So you touched on it briefly during your prepared remarks, but what has your experience been regarding how AI is affecting your technologies? Because clearly, that isn't merely today's buzzword, but is growing more and more significant when it comes to these technological breakthroughs.

Matt Foehr

executive
#12

Yes, Joe, thank you; this is Matt. And clearly, AI, and you've followed the business for some time, tracked the business for some time, AI, big data management, deep learning, machine learning—these are all areas where we've been engaged and have been leaning in for quite a while, really the past few years or longer. It happens naturally when you operate in the sort of cutting-edge science world that we occupy. And it's an area we've been leaning into much more. Last year, last May, we introduced OmniDeep, which is our suite of in silico AI machine learning tools that draw on large multi-species databases. We rolled that out in May of last year, but in reality, many of our partners knew we were in this space well before that. Really, what OmniDeep is built to do is harness deep learning and truly deliver the best of our in vivo engineering capabilities along with our in silico capabilities. We rely on high-quality input data; we have deep learning models that we've presented at scientific conferences which use variational autoencoders to truly expand insights we already obtain from our screening hits to infer function across other untested areas, suggesting new hits, and then running those through in silico developability filters. We truly are employing AI and leveraging it here and have done so for quite a while. It genuinely gives our partners new, larger-scale discovery workflows with big data, lets us apply optimization tools for existing discovery campaigns, and truly supplies high-quality training data, so to speak, for a lot of those capabilities we've built up over time. Hopefully, that's useful to you.

Joe Pantginis

analyst
#13

No, it really does, Matt. I value that context. I suppose my following question, or actually my final one, pertains to both the expansion and the count of partners you've been observing, along with attrition rates. So I'm wondering, given that you possess long-term data—not just from the spinout, but also from the Ligand days and from OmniAb's very beginning—is there a kind of steady state in terms of partner growth that you're observing? Clearly, we have the charts showing partner counts rising, but how does that connect to the visibility of your BD conversations regarding how many are mature and the attrition rates—does that stay consistent across time, or do you notice significant volatility?

Matt Foehr

executive
#14

Yeah, Joe. So, like you said, we always give our numbers after subtracting for attrition among partners, programs, and clinical and approved products that are currently active. The reason is we think that gives the best view of the business right now and where it's going. Attrition, of course, is totally normal and very much expected in pharma discovery and development. It can differ depending on the stage. And as we gain more experience with programs and our portfolio, we're seeing some interesting things, though I'd say it's still early in some ways. One thing worth pointing out is that timelines for each stage may vary across programs. It depends on the therapeutic area, the amount of work needed because of different factors, what the partner is looking to invest, and whether tasks are handled simultaneously or one after another, among other things. So at minimum, you could see variation between one phase and the next. That said, I want to flag our preclinical portion, which appears as the orange slice in the pie charts on our slides. The bar is set quite high for anything we move into preclinical. These are programs that are in pre-IND studies. To be clear, we haven't lost any programs at the preclinical stage. That said, the duration a program spends in preclinical work can shift depending on the situation — an oncology program, for instance, might reach the clinic faster than one aimed at a CNS, metabolic, or inflammation target. So the amount of time spent in each stage does vary. What also varies is the rate at which programs drop out, and that differs between stages — discovery, preclinical, and clinical.

Joe Pantginis

analyst
#15

Understood. That's really useful context. Thanks, Matt.

Matt Foehr

executive
#16

Hi, Stephen, could your line be muted?

Chad Wiatrowski

analyst
#17

Hey, you guys. How's it going? On the sales rep.

Matt Foehr

executive
#18

Alright, Chad.

Chad Wiatrowski

analyst
#19

How many people are on the sales team, and could you break down where they're located? I believe you brought up the U.S., Singapore, and the E.U. Are all of those reps selling the full range of transgenic animals, including the ones that just came out?

Matt Foehr

executive
#20

Chad, yes, it's Matt here. Appreciate that. OK, so our business development group is made up of highly seasoned individuals who possess strong scientific backgrounds in addition to solid business experience. As a result, we have a staff of BD experts located in the United States. We maintain a presence on the West Coast as well as on the East Coast, and we also cover the central portion of the U.S. In addition, we have one BD professional situated in the U.K. who handles Europe. We likewise have alliance team members stationed in Europe who provide support and take part in our business development activities. And our presence in Asia is located in Singapore, though it covers the entirety of Asia. So that's how our BD team is structured.

Chad Wiatrowski

analyst
#21

Understood, thank you. Then regarding Sugemalimab, would the Chinese green light for that extra indication, or a possible U.S. nod, trigger any sort of milestone payment for you? Or have those older-style big upfront milestones mostly already passed through the business following the Teclistamab ones this year?

Kurt Gustafson

executive
#22

Okay, so when it comes to Sugemalimab in particular, the approval milestones have basically already been achieved. So honestly, the sole remaining item for that program is collecting royalties; as a result, we bring in modest yet fairly consistent royalty income from China, and to the degree that the drug gains approval in further territories, our expectation would be that this leads to extra sales, which in turn leads to extra royalties for us; however, there are essentially no other one-time payments headed our way tied to milestones for that program.

Chad Wiatrowski

analyst
#23

That's helpful. Thanks for the questions, guys.

Kurt Gustafson

executive
#24

Of course.

Stephen Willey

analyst
#25

Yes, you should be able to pick me up at this point. My apologies for the earlier issue.

Matt Foehr

executive
#26

Yes, Steve, we're able to hear you.

Stephen Willey

analyst
#27

Great. So my understanding is that among the 6 programs that went into the clinic over the last year, 5 of them — or 5 of them had some downstream royalty involvement, correct? As I recall, just the Roche asset was an older, fully paid-up license. Now, looking at the programs currently active across different phases of discovery and development, how many of those carry downstream royalty participation? Have you largely gotten through those fully paid licensing deals?

Kurt Gustafson

executive
#28

Okay, Steve — Kurt here. I'd bring you back to what we discussed during our research and technology day, which happened back in November of last year. Only a small number of our programs had something like a prepaid license, or a grandfather license, so to speak, where no economics exist for us. We mentioned that this applied to 2% of the whole portfolio, and that figure remains the same. I doubt we'll refresh that figure each quarter, but it's still accurate as of today. Therefore, the overwhelming majority of our programs do include downstream economics. Naturally, no two programs are alike, yet very few possess this type of structure involving a prepaid license.

Matt Foehr

executive
#29

Right, and I'll throw in a bit more context there as well, Steve — every one of those, that 2%, as we sign new agreements, that figure is declining throughout the portfolio. Those were agreements we took on, so to speak, rather than ones we'd enter into now, by and large.

Stephen Willey

analyst
#30

Right, I’d lost track of the fact that you all had mentioned that during November. And then, Kurt, you were sort of bringing up the expectation of a meaningful drop in cash use for 2025 compared with 2024 on a year-over-year basis. I believe you may have touched on that somewhat when it comes to milestones, but are there additional factors you’re considering as you look at that 2025 cash use figure? Does a royalty piece play into it? Does an ion channel partnership piece play into it? We’d simply be interested in knowing whether that’s entirely milestones or.

Kurt Gustafson

executive
#31

Right. I'd say that accounts for nearly all of it. I went over how our revenue is shaped, I believe. And in the nearer term and mid-term, we believe milestones will provide the bulk of the growth in revenue. Once you look further ahead — let's say 3, 4, 5 years out — I believe royalties will become a larger piece of the revenue growth narrative; but yes, in terms of how we're approaching this and basically, Steve, we set out every one of the partner programs, and we simply estimate what the timelines look like. And once we reach 2025, there are simply many more catalysts when it comes to events we believe might possibly occur. We can't know with certainty if they occur, but as I mentioned, we use a probabilitized approach whenever we examine those. But the more events there are, the more chances for extra inflows from milestones. But yes, I mean, returning to your fundamental question, there isn't anything else out there. Milestone payments will drive the short term.

Chad Wiatrowski

analyst
#32

All right, thanks. And then perhaps as a final point, Matt, I believe you mentioned something about how the partnerships on ion channels and transporters with Roche and GSK could gain greater visibility among investors, maybe during the coming year or thereabouts. Could you share anything further regarding the sort of headway being achieved, or anything at all you're able to tell us? I realize that the communication side here is being handled by Roche and GSK, but.

Matt Foehr

executive
#33

Right. Right. And as we've pointed out previously, there are 5 ion channel programs in active discovery with GSK and Roche. If you add together all the milestones across those 5 programs, the figure exceeds $1 billion; by and large they sit in neurodegeneration as well as other spaces where ion channels play a critical role. We truly possess a deep legacy in the discovery and screening of ion channels. Every one of them remains at the discovery stage. That point deserves emphasis. Still, we're enthusiastic about the ongoing work and about the advances we anticipate delivering across those programs during this year.

Chad Wiatrowski

analyst
#34

Got it. I appreciate you fielding these questions.

Analyst

analyst
#35

Hey everyone. Jack here. I'm calling in for Matt; we've only got a single item to ask. There appears to have been a clear step-up in activity as fiscal 2023 wrapped up. Did that momentum continue into Q1, or what does the quarter look like thus far?

Matt Foehr

executive
#36

Yes, Jack. Thank you. Naturally, once we formally report, we'll give an update on our Q1 metrics. And of course, we're in touch with partners daily, constantly, and from a business development standpoint we're always pursuing deals. That said, we also receive partner reports at different moments within the quarter, frequently close to its finish. So those figures will come out when we report, probably around May, for Q1.

Analyst

analyst
#37

All right, thanks.

Analyst

analyst
#38

Hello there, Alex here, calling in from Robin.

Matt Foehr

executive
#39

Hello, Alex.

Analyst

analyst
#40

Things have been going really well. Hi there, how are you doing? Yes, the headway has truly been fantastic. We're happy to see it. We started wondering — since the pipeline has matured further and there are additional molecules in the clinic at different stages — will anything shift in the way you go after new partnerships and the deals you're weighing with new partners? Please tell us whether the strategy will change at all, given you may now be at a different stage than previously.

Matt Foehr

executive
#41

Yes, Alex. What I'd say is that we are very mission-driven, focused on speeding up development of innovative medicines for our partners by concentrating on licensing drug discovery technologies. That's our approach, and we're strongly dedicated to it. I believe our partners genuinely appreciate this. Thanks to the expansion and quantity of partnerships we've established, the close ties we have with our partners truly shape our confidence and our priorities regarding investment in technology. So we feel terrific about our mission, terrific about the momentum we're generating alongside partners, and we will remain with that strategy. For this business, that strategy is the correct one. We hear this constantly from partners, particularly some of the more recent ones. I'd mention the new large pharma partners we brought on during the last year, who were drawn to our technology because of our sharply defined emphasis on advancing technology and serving their needs both at present and going forward; so yes, we feel terrific about the business we're constructing and our capacity to deliver on it.

Analyst

analyst
#42

That sounds excellent. If I may ask one more thing — we're quite eager to learn about the enthusiasm surrounding the OmnidAb program along with that new scaffolding technology it incorporates. How are the partnerships responding, and are there any remaining opportunities not yet explored? What kinds of technology might their investors expect to see down the road? Is there an additional stage currently in development, or anything you could hint at regarding hurdles that still require attention?

Matt Foehr

executive
#43

Well, this is something that stirs a lot of excitement in me, as anybody on this team can confirm. Our plan includes a fairly thrilling investment strategy focused on emerging technologies. Each year we get better at deploying these new technologies efficiently. Much of that improvement stems from money we've put into our facilities, our workflows, and similar areas in recent years. Broadly speaking, I'm enthusiastic about what we're doing with novel scaffolds, which sits in that lower left-hand portion of where our technology is headed. Beyond that, there's expanded capability and effort in big data management and related fields that I believe will help programs and speed them up, plus additional scalability efforts involving screening and other areas; this gets quite technical quite quickly, but we'll share more on these topics at the big antibody discovery conferences later in the year, such as PEGS and AETC. Our internal innovation plan has us excited.

Analyst

analyst
#44

All right. That's excellent to hear; and yes, I believe everyone is looking forward to 2024 and what comes after. Many thanks.

Matt Foehr

executive
#45

Thanks.

Conor McNamara

analyst
#46

Hey everyone. Thanks for taking our questions. We appreciate it. Kurt, this one's directed at you — I appreciate the detail you provided regarding how you adjust program progression on a probability basis across the year. If you consider 2023 and your position twelve months back, how did the year measure up against what your model would have projected? And did financing play any role in where you landed relative to what you'd anticipated regarding this year's probability?

Kurt Gustafson

executive
#47

Regarding the near term, when I bring up the probabilistic method, that's typically maybe aimed at years ahead; for the year we're in, when we establish guidance, like we do for 2024, we usually don't assess things on a probabilitized basis. Instead, we essentially determine, through our discussions with partners, whether it's in or out. So the near term works somewhat differently since our visibility is a bit greater. Take a partner who publicly states, for instance, "We expect to begin a Phase 3 study or a Phase 2 study in Q3 of this year." That leads us to essentially say, "Alright, we're going to treat that as happening." So I'd say things went mostly as anticipated. A program or two that partners had said would land in 2023 wound up moving, say, to the following quarter or something along those lines. Still, by and large, I'd say things were pretty much on point.

Conor McNamara

analyst
#48

Great, thank you. From a competition angle, if you tried to size up all the programs out there—whether they're heading into the clinic or still in discovery—do you have any visibility into what portion of them you're actually capturing? And how has that share shifted across the past several years?

Matt Foehr

executive
#49

Yes, Conor. When it comes to discovery campaigns or discovery programs, there isn't much in the way of, let's call it, comprehensive data available. One thing that's unambiguous is the scale of the untapped opportunity in antibody-based discovery—and I use that term broadly, since plenty of fascinating and promising developments are happening in novel modalities built on antibodies, though sometimes these get labeled as, you could say, Frankenstein molecules. We're genuinely enthusiastic about where our technology fits into that picture. That said, there really isn't solid data you can turn to for precise share figures regarding discovery campaigns. What I can tell you is that this untapped space is enormous and expanding, so I'd frame it that way. Much of that stems from several factors that are now fairly well established, which keep drawing more and more sponsors toward antibody-based modalities—whether it's superior clinical success rates relative to small molecules, or things such as dynamics tied to the IRA, or other forces pushing additional investment into antibodies. Still, providing you with a precise market figure on that is difficult.

Conor McNamara

analyst
#50

Understood. I appreciate you taking the questions, everyone.

Kurt Gustafson

executive
#51

Sure thing. Thank you, Conor.

Matt Foehr

executive
#52

Excellent. I appreciate all of you being here on today's call. We're eager to continue sharing how we're doing and to talk with you again when we report for the upcoming quarter. Naturally, we'll be present at a number of conferences during this spring, so we hope to connect with investors there. Until then, thank you for your interest in OmniAb, and thanks once more.

Operator

operator
#53

That wraps up the conference call for today, everyone. We appreciate you joining us. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.